logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
AVBP
ArriVent BioPharma, Inc.
29.51
1 x 29.63
2 x 29.72
bid
ask
-
0.49
1.63%
36 @ 04:00 PM
29.51 +0.00 (0.00%)
Ytd46.67%
1y58.49%
29.13
day range
30.00
17.17
52 week range
34.74
Open29.99Prev Close30.00Low29.13High30.00Mkt Cap1.37B
Vol434.10KAvg Vol565.58KEPS-3.47P/E-8.50Forward P/E-7.87
Beta1.37Short Ratio15.41Inst. Own94.09%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-1150-d Avg31.73200-d Avg25.841yr Est44.40

AVBP News

Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP
defenseworld.net
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP

Dimensional Fund Advisors LP lifted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) b

ArriVent BioPharma Reports Second Quarter 2026 Financial Results
globenewswire.com
ArriVent BioPharma Reports Second Quarter 2026 Financial Results

NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent

Affinity Asset Advisors LLC Purchases 25,000 Shares of ArriVent BioPharma, Inc. $AVBP
defenseworld.net
Affinity Asset Advisors LLC Purchases 25,000 Shares of ArriVent BioPharma, Inc. $AVBP

Affinity Asset Advisors LLC lifted its position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP)

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case
seekingalpha.com
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulat

ArriVent BioPharma Reports First Quarter 2026 Financial Results
globenewswire.com
ArriVent BioPharma Reports First Quarter 2026 Financial Results

NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent)

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
globenewswire.com
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initi

NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent)

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts
defenseworld.net
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have earned an average recommend

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
zacks.com
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investor

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
zacks.com
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Plac

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
zacks.com
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed c

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib
seekingalpha.com
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
globenewswire.com
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dua

NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVen

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
zacks.com
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Mo

The average of price targets set by Wall Street analysts indicates a potential upside of 70.4% in Ar

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
zacks.com
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

Here is how ArriVent BioPharma, Inc. (AVBP) and Ocugen (OCGN) have performed compared to their secto

ArriVent BioPharma Reports Full Year 2025 Financial Results
globenewswire.com
ArriVent BioPharma Reports Full Year 2025 Financial Results

NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVen

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Moderate Buy” by Analysts
defenseworld.net
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Moderate Buy” by Analysts

ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) has been given an average recommendation o

Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact
gurufocus.com
Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact

Insight into Leon Cooperman (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Leon Cooperman (Tra

$207B Market Shift: The Race for Fast Track Approval in Oncology
prnewswire.com
$207B Market Shift: The Race for Fast Track Approval in Oncology

/PRNewswire/ -- USANewsGroup.com News Commentary - The FDA isn't just approving drugs; they are comp

ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy
seekingalpha.com
ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy

ArriVent BioPharma (AVBP) is a cautious BUY, driven by furmonertinib's late-stage potential in uncom

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts
seekingalpha.com
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts

ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib's near-term clinical catalysts and